• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by Translational Development Acquisition Corp.

    5/11/26 2:08:33 PM ET
    $TDAC
    Get the next $TDAC alert in real time by email
    false --12-31 2025 FY 0001926599 00-0000000 0001926599 2025-01-01 2025-12-31 0001926599 TDAC:UnitseachconsistingofoneClassAordinaryshareMember 2025-01-01 2025-12-31 0001926599 TDAC:ClassAordinarysharesMember 2025-01-01 2025-12-31 0001926599 TDAC:RedeemablewarrantsMember 2025-01-01 2025-12-31 0001926599 2025-06-30 0001926599 us-gaap:CommonClassAMember 2026-03-30 0001926599 us-gaap:CommonClassBMember 2026-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-K/A

    (Amendment No. 2)

     

    (Mark One)

     

    x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2025

     

    or

     

    ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from to

     

    Commission File Number 001-42451

     

    TRANSLATIONAL DEVELOPMENT ACQUISITION CORP.
    (Exact name of registrant as specified in its charter)

     

    Cayman Islands    N/A
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

         
    52 E. 83rd Street,    
    New York, New York    10028
    (Address of principal executive offices)   (Zip Code)

     

    (917) 979-3072

    (Registrant’s telephone number, including area code)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading
    Symbol(s)
      Name of each exchange on
    which registered
    Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant  TDACU  The Nasdaq Stock Market LLC
    Class A ordinary shares, $0.0001 par value per share  TDAC  The Nasdaq Stock Market LLC
    Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50  TDACW  The Nasdaq Stock Market LLC

     

    Securities registered pursuant to section 12(g) of the Act: None.

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

     

    Yes ¨ No x

     

    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

     

    Yes ¨ No x

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

     

    Yes x No ¨

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

     

    Yes x No ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

           
    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ¨

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

     

    Yes x No ¨

     

    The aggregate market value of the registrant’s outstanding Class A Ordinary Shares, other than shares held by persons who may be deemed affiliates of the registrant, computed by reference to the closing price for the Class A Ordinary Shares on June 30, 2025, the last business day of the registrant’s most recently completed second fiscal quarter, as reported on the Global Market tier of The Nasdaq Stock Market LLC, was $177,675,000.

     

    As of March 30, 2026, 17,250,000 Class A ordinary shares and 4,657,500 Class B ordinary shares were issued and outstanding.

     

    DOCUMENTS INCORPORATED BY REFERENCE

     

    None.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Translational Development Acquisition Corp. (the “Company,” “we,” “us” or “our”) is filing this Amendment No. 2 on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026 (the “Original Filing”), as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on May 6, 2026 (“Amendment No. 1”). Capitalized terms not otherwise defined in this Amendment shall have the same meanings assigned to such terms in the Original Filing, as amended by Amendment No. 1.

     

    We are filing this Amendment in response to a comment letter from the SEC, dated May 7, 2026, in connection with its review of Amendment No. 1. The sole purpose of this Amendment is to amend and restate in its entirety Part II, Item 9A, “Controls and Procedures,” to revise the Company’s conclusion regarding the effectiveness of its disclosure controls and procedures as of December 31, 2025 to state that such disclosure controls and procedures were not effective. Part IV, Item 15, “Exhibits and Financial Statement Schedules,” is also amended solely to include new certifications of the Company’s principal executive officer and principal financial officer required by Section 302 of the Sarbanes-Oxley Act of 2002, as amended, filed as Exhibits 31.1 and 31.2, and certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 furnished as Exhibits 32.1 and 32.2.

     

    Except as expressly described above, this Amendment does not amend, update or change any other items or disclosures contained in the Original Filing, as amended by Amendment No. 1, and does not reflect or purport to reflect any information or events occurring after the filing date of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing, Amendment No. 1 and the Company’s other filings with the SEC.

     

     

     

     

    TABLE OF CONTENTS

     

    PART II    
    Item 9A.   Controls and Procedures
    PART IV    
    Item 15.   Exhibits and Financial Statement Schedules
    SIGNATURES

     

     

     

     

    PART II

     

    Item 9A. Controls and Procedures.

     

    Evaluation of Disclosure Controls and Procedures

     

    Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Annual Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our chief financial officer (our “certifying officer”), the effectiveness of our disclosure controls and procedures as of December 31, 2025, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our certifying officer concluded that, as of December 31, 2025, our disclosure controls and procedures were not effective.

     

    We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

     

     

     

     

    Management’s Report on Internal Controls Over Financial Reporting

     

    As required by SEC rules and regulations implementing Section 404 of the Sarbanes-Oxley Act, our Management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:

     

    (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our Company,

     

    (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our Management and directors, and

     

    (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

     

    Because of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making these assessments, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on our assessments and those criteria, Management determined that we maintained effective internal control over financial reporting as of December 31, 2025.

     

    This Report does not include an attestation report of our internal controls from our independent registered public accounting firm due to our status as an emerging growth company under the JOBS Act.

     

    Changes in Internal Control over Financial Reporting

     

    There were no changes in our internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

     

     

     

     

    PART IV

     

    Item 15. Exhibits and Financial Statement Schedules.

     

    (a) The following documents are filed as part of this Form 10-K/A:

     

      (1) Financial Statements:

     

    The consolidated financial statements required to be filed in the Form 10-K/A are listed in Part IV, Item 15 of the Original Filing.

     

      (2) Financial Statement Schedules:

     

    None.

     

      (3) Exhibits

     

    We hereby file as part of this Annual Report the exhibits listed in the attached Exhibit Index. Exhibits which are incorporated herein by reference can be inspected and copied at the public reference facilities maintained by the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Copies of such material can also be obtained from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates or on the SEC website at www.sec.gov.

     

     

     

     

    Exhibit
    No.
      Description
    3.1   Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on August 26, 2022)
    3.2   Amended and Restated Memorandum and Articles of Association of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    4.1   Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on November 20, 2024)
    4.2   Specimen Class A Ordinary Share Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on November 20, 2024)
    4.3   Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on November 20, 2024)
    4.4   Warrant Agreement, dated December 23, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    4.5   Description of the Registrant’s Securities, as amended (incorporated by reference to Exhibit 4.5 to the Annual Report on Form 10-K filed with the Securities & Exchange Commission on March 31, 2025)
    10.1   Promissory Note, executed on May 25, 2022, issued by the Registrant to Stone Capital Partners LLC (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on August 26, 2022)
    10.2   Amended and Restated Promissory Note, executed on July 10, 2024, issued by the Registrant to Stone Capital Partners LLC (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on October 22, 2024)
    10.3   Second Amended and Restated Promissory Note, executed on August 9, 2024, issued by the Registrant to Stone Capital Partners LLC (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on October 22, 2024)
    10.4   Letter Agreement, dated December 23, 2024, by and among the Company, its officers and directors and the Sponsor (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)

     

     

     

     

    10.5   Investment Management Trust Account Agreement, dated December 23, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as trustee (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    10.6   Registration Rights Agreement, dated December 23, 2024, by and among the Company and certain security holders (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    10.7   Securities Subscription Agreement, dated May 25, 2022, between the Registrant and Stone Capital Partners LLC (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on August 26, 2022)
    10.8   Private Placement Warrants Purchase Agreement, dated December 23, 2024, by and between the Company and the Sponsor (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    10.9   Private Placement Warrants Purchase Agreement, dated December 23, 2024, by and between the Company and the Underwriter (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    10.10   Form of Indemnity Agreement (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on November 20, 2024)
    10.11   Administrative Services Agreement, dated December 23, 2024, by and between the Company and the Sponsor (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 27, 2024)
    10.12   Amendment No. 1 to Securities Subscription Agreement, dated August 29, 2024, between the Registrant and Stone Capital Partners LLC (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on October 22, 2024)
    10.13   Assignment and Novation Agreement dated October 15, 2024, among the Registrant, Stone Capital Partners LLC and TDAC Partners LLC (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on October 22, 2024)
    10.14   Novated Securities Subscription Agreement dated October 15, 2024 between the Registrant and TDAC Partners LLC (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on October 22, 2024)
    10.15   Promissory Note, dated August 8, 2025 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on August 14, 2025)
    14   Code of Ethics (incorporated by reference to Exhibit 14 to the Registration Statement on Form S-1 filed with the Securities & Exchange Commission on November 20, 2024)
    19   Insider Trading Compliance Policy and Procedures (incorporated by reference to Exhibit 19 to the Annual Report on Form 10-K filed with the Securities & Exchange Commission on March 31, 2025) 
    21   Subsidiaries of the Registrant (incorporated by reference to Exhibit 21 to the Annual Report on Form 10-K filed with the Securities & Exchange Commission on March 31, 2025) 
    24   Power of Attorney (included on the Signatures page of the Original Filing)
    31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    31.2*   Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
    32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
    97   Policy For Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97 to the Annual Report on Form 10-K filed with the Securities & Exchange Commission on March 31, 2025)
    101.INS   Inline XBRL Instance Document
    101.SCH   Inline XBRL Taxonomy Extension Schema Document
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

     

    *    Filed herewith.

     

    ** Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      TRANSLATIONAL DEVELOPMENT ACQUISITION CORP.
    Date: May 11, 2026    
      By: /s/ Michael B. Hoffman
        Michael B. Hoffman
        Chief Executive Officer

     

     

     

    Get the next $TDAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TDAC

    DatePrice TargetRatingAnalyst
    9/21/2021$16.00Outperform
    Northland Capital Markets
    More analyst ratings

    $TDAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital Markets initiated coverage on Trident Acquisitions with a new price target

    Northland Capital Markets initiated coverage of Trident Acquisitions with a rating of Outperform and set a new price target of $16.00

    9/21/21 8:09:12 AM ET
    $TDAC

    $TDAC
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Translational Development Acquisition Corp.

    SCHEDULE 13G - Translational Development Acquisition Corp. (0001926599) (Subject)

    6/2/26 2:23:29 PM ET
    $TDAC

    SEC Form DEFA14A filed by Translational Development Acquisition Corp.

    DEFA14A - Translational Development Acquisition Corp. (0001926599) (Filer)

    5/28/26 5:21:02 PM ET
    $TDAC

    SEC Form DEF 14A filed by Translational Development Acquisition Corp.

    DEF 14A - Translational Development Acquisition Corp. (0001926599) (Filer)

    5/27/26 5:07:50 PM ET
    $TDAC

    $TDAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman and CEO Hoffman Michael B

    4 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    5/29/26 4:05:16 PM ET
    $TDAC

    SEC Form 3 filed by new insider Jarratt Christopher Kenneth

    3 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    1/6/25 4:05:09 PM ET
    $TDAC

    SEC Form 3 filed by new insider Keith Curtis T

    3 - Translational Development Acquisition Corp. (0001926599) (Issuer)

    12/20/24 6:59:32 PM ET
    $TDAC

    $TDAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.

    ProLogium reached commercial-scale manufacturing for solid-state batteries in 2013, later delivered the world's first solid-state battery demo car with ENOVATE Motor in 2019. ProLogium has shipped a total of over 2.4 million battery cells to customers since 2013, of which more than 800,000 are its 3rd-generation batteries from the Gigafactory in Taiwan. With a portfolio of 1,100+ patents, ProLogium has introduced its 4th-generation superfluidized inorganic solid-state battery solution with zero thermal runaway, high energy density, low temperature performance, fast charging, competitive cost, and commercial readiness. Pre-money valuation of ProLogium is expected to be approximately $3.8 bill

    5/27/26 7:00:00 AM ET
    $TDAC

    Lottery.com to Present at the 10th Annual Gateway Conference on September 9, 2021

    AUSTIN, TX / ACCESSWIRE / September 2, 2021 / AutoLotto, Inc. ("Lottery.com"), a leading technology company that is transforming how, where and when the lottery is played, announced today that its management will participate in the virtual 10th Annual Gateway ConferenceLottery.com's management is scheduled to present on Thursday, September 9th at 8:00 a.m. Pacific time, with one-on-one meetings to be held throughout the day. The presentation will be webcast live and available for replay here.To receive additional information, request an invitation, or schedule a one-on-one meeting, please email conference@gatewayir.com.On Feb. 21, 2021, Lottery.com entered into a definitive agreement with Tr

    9/2/21 4:15:00 PM ET
    $TDAC

    10th Annual Gateway Conference to Virtually Showcase Leading Companies on September 8-9, 2021

    Executives from a Range of Industries to Present to 500+ Investors and AnalystsNEWPORT BEACH, CA / ACCESSWIRE / August 24, 2021 / The Gateway Conference is back for its 10th year and will showcase leading public and private companies virtually on September 8th and 9th.Attendees will have the opportunity to discover and learn about a select group of compelling companies across a wide range of industries, including consumer & wellness, financials, internet & business services, industrials, technology & electric vehicles, and SPACs.The invitation-only conference provides investors and analysts a unique opportunity to gain valuable insights during two days of presentations and one-on-one meeting

    8/24/21 1:30:00 PM ET
    $AROC
    $AUTO
    $AWRE
    Natural Gas Distribution
    Utilities
    Business Services
    Consumer Discretionary

    $TDAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - Trident Acquisitions Corp. (0001673481) (Subject)

    2/12/21 4:30:21 PM ET
    $TDAC